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1H NMR spectroscopyHuntington disease (HD) is a hereditary brain disease. Although the causative gene has been found, the exact
mechanisms of the pathogenesis are still unknown. Recent investigations point to metabolic and energetic
dysfunctions in HD neurons.
Both univariate and multivariate analyses were used to compare proton nuclear magnetic resonance spectra
of serum and cerebrospinal ﬂuid (CSF) taken from presymptomatic HD transgenic rats and their wild-type
littermates. N-acetylaspartate (NAA), was found to be signiﬁcantly decreased in the serum of HD rats
compared to wild-type littermates. Moreover, in the serum their levels of glutamine, succinic acid, glucose
and lactate are signiﬁcantly increased as well. An increased concentration of lactate and glucose is also found
in CSF. There is a 1:1 stoichiometry coupling glucose utilization and glutamate cycling. The observed increase
in the glutamine concentration, which indicates a shutdown in the neuronal-glial glutamate-glutamine
cycling, results therefore in an increased glucose concentration. The elevated succinic acid concentration
might be due to an inhibition of succinate dehydrogenase, an enzyme linked to the mitochondrial respiratory
chain and TCA cycle. Moreover, reduced levels of NAA may reﬂect an impairment of mitochondrial energy
production. In addition, the observed difference in lactate supports a deﬁciency of oxidative energy
metabolism in rats transgenic for HD as well.
The observed metabolic alterations seem to be more profound in serum than in CSF in presymptomatic rats.
All ﬁndings suggest that even in presymptomatic rats, a defect in energy metabolism is already apparent.
These results support the hypothesis of mitochondrial energy dysfunction in HD.stry, University of Antwerp,
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Huntington disease (HD) is an autosomal dominant neurodegen-
erative disorder, characterized by progressive motor, cognitive and
psychiatric dysfunctions. Although the disease can occur at any age,
the median age of onset is 40 years. Most patients die one to two
decades after disease onset.
HD is caused by a mutation in the gene coding for the protein
huntingtin. The exact function of this protein is still unknown. Normal
individuals have a CAG-trinucleotide repeat length of less than 37 [1].People whose CAG repeat length exceeds this number will develop
HD. The length of the CAG expansion is proportional to the severity of
the disease and inversely proportional to the age of onset [2]. At
present, the exact mechanism of the HD pathology is still unknown.
However, recent evidence points to metabolic and energetic dysfunc-
tion in HD neurons [2–4]. Better knowledge about this mechanism is
expected to lead to more appropriate analyses, which in turn should
result in a better understanding of the disease. Moreover, this will
help to direct the quest for improved treatments in the proper
direction.
According to Nicholson et al. [5], metabolomics is deﬁned as ‘the
quantitative measurement of the dynamic multiparametric metabolic
response of living systems to pathophysiological stimuli or genetic
modiﬁcations’. Since 1999, applications of this technique have
emerged in other ﬁelds (e.g. environmental sciences) [6]. Metabolites
in bioﬂuids are in dynamic equilibriumwith those in cells and tissues.
A healthy individual attempts to retain the concentration of
metabolites in cells and tissues constant by homeostasis. Abnormal
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compositions. Various analytical techniques are available to detect
low molecular weight metabolites. The ones most commonly applied
in metabolomic studies are nuclear magnetic resonance spectroscopy
(NMR) and mass spectrometry (MS). The latter is frequently used in
combination with a chromatographic separation technique (liquid
chromatography, gas chromatography, etc.) [7]. Although NMR is less
sensitive thanMS, this technique offers some important advantages. It
is a high-throughput analysis that does not require any preceding
chromatographic separation or puriﬁcation procedure. Additionally,
sample preparation is very straightforward. Furthermore, it is a non-
destructive method capable of detecting all non-exchangeable pro-
tons, provided they are present above a certain threshold concentra-
tion (μM concentrations). Moreover, the measurements are very
reproducible and inexpensive on a per sample basis [8–10]. All these
advantages have contributed to the application of NMR spectroscopy
in clinical diagnoses of diseases and in the follow-up of subjects
participating in medical treatment studies [11].
The NMR spectrum of a bioﬂuid is generally extremely complex in
nature, since each molecule present in the bioﬂuid gives rise to one or
several peaks in most cases. Moreover, many peaks show some ﬁne
structure and splittings which cause a prominent overlap of signals
originating from different molecules [12]. Visual inspection of the
spectra will therefore only reveal a small percentage of the available
information [13].
Spectral interpretation can be simpliﬁed by applying automatic
data reduction methods. Subsequently, these reduced datasets can be
analyzed with univariate [2,14–22] or multivariate [13,23–27]
statistical methods.
In this study we applied 1H NMR spectroscopy in order to
disentangle the metabolic proﬁle of serum and cerebrospinal ﬂuid
(CSF) from a rat model for HD. Both univariate and multivariate
statistical analyses were applied in a search for pathology speciﬁc
differences. It is anticipated that these investigations lead to a gain in
knowledge about the pathogenesis of HD and make it possible to
identify some potential biomarkers.
2. Materials and methods
2.1. Animals
Transgenic HD rats carrying a truncated huntingtin cDNA fragment
with 51 CAG repeats under the control of the native rat huntingtin
promoter, and their wild-type littermates were used [28]. The
expressed gene product was 75 kDa, corresponding to 22% of the
full-length huntingtin (cDNA positions 324–2321, amino acid posi-
tions 1–709/825, corresponding to exons 1–16), which are under the
control of 886 bp of the rat huntingtin promoter (positions 900 to 15).
Genotyping was carried out as previously described [28]. The number
of CAG repeats was analyzed in a subset of transgenic rats using these
primers: cggctgaggcagcagcggctgt (forward) and ccttcgagtccct-
caagtccttc (reverse). The reverse primer is labelled at the 5′ end
with the ﬂuorescent dye Cy5. The PCR amplicon length was then
analyzed on the Beckman coulter sequencer (CEQ 8000 Cycle
Sequencer, Krefeld, Germany). In more than 15 generations only a
small variation of ±1–2 CAGs were observed in transgenic rats of HD.
Also for this study, in a subset of animals, the CAG-length was checked
and it was found to be 51±2 CAGs. After genotyping, rats were
housed in gender- and genotyped matched groups of two, according
to FELASA recommendations. All rats were kept under a 12:12 hours
light–dark cycle with lights on at 06.00 a.m. and food (Altromin lab
chow pallets, Altromin standard diet: 1320; Lage, Germany) and tap
water available ad libitum. All research and animal care procedures
had been approved by the district government of Tuebingen,
Germany, and followed principles described in the European Com-
munity's Council Directive of 24th November, 1986 (86/609/EEC).For this study, we used serum and CSF from female, transgenic HD
rats (n=10 for serum and n=8 for CSF) at an age of two months and
compared these with age-matched wild-type (WT) littermates
(n=12 for serum and respectively 9 for CSF). We are aware of the
fact that the number of samples used in this study is rather small.
However, this was determined by keeping in mind the well-being of
animals and in order to reduce costs. Moreover, in the literature a lot
of studies where even less samples per group are investigated, can be
found [15,27,29–32].
2.2. Sample collection and preparation
2.2.1. CSF samples
Rats were sacriﬁced by CO2 inhalation and immediately exsangui-
nated. Subsequently, each animal was placed prone onto the
stereotaxic instrument. A sagittal incision of the skin was made
inferior to the occiput. The subcutaneous tissue and neck muscles
through the midline were bluntly separated. Next, the rat was laid
down in a way that the bodymade a 135° angle with the ﬁxed head. In
this angle, the dura mater of cisterna magna was exposed sufﬁciently.
The dura was then penetrated with an insulin syringe and CSF was
drawn. All samples were transferred into polypropylene tubes,
immediately snap frozen in liquid nitrogen and stored at −80 °C
until shipped for NMR analysis. Upon arrival, CSF samples were
immediately stored at −80 °C until measurement.
All CSF samples (40 μL) were simultaneously lyophilized. In cases
where less than 40 μL of CSF was available, the total available volume
was lyophilized. The freeze-dried samples were then stored at−20 °C
in sealed vials until analysis. In order to keep the time spent at room
temperature to a minimum, samples were randomly divided in ﬁve
batches. Samples gathered in one batch were prepared together. Prior
to NMR analysis, each sample was reconstituted in 8 μL sodium
phosphate buffer (50 mM dissolved in D2O, pH=7.05) containing
0.05 mM sodium azide in order to prevent bacterial contamination.
Finally, this volume was transferred to a 1 mm NMR tube.
2.2.2. Serum samples
Samples were taken as done previously [33]. In short: rats were
sacriﬁced with CO2 and blood was drawn directly from the heart. All
rats were tested for diabetes immediately after sample collection. The
blood was incubated for 1 h at 37 °C, followed by centrifugation for
30 min at 3000 ×g. The serum was collected and immediately stored
at −80 °C until shipped for NMR analysis. Upon arrival, serum
samples were immediately stored at −80 °C until measurement.
In order to keep the time spent at room temperature to a
minimum, samples were randomly divided in three groups. Samples
assembled in one group were prepared together. Just before their
acquisition, samples were thawed to room temperature. An aliquot of
serum (250 μL) from each sample was mixed with 300 μL of an
aqueous saline solution. In this way, each sample contains 0.1 M NaCl
and 10% D2O. The addition of an internal standard like DSS is
prohibited by its interaction with proteins present in the sample.
Subsequently, the total volume was transferred to a 5 mm NMR tube.
2.3.
1
H NMR spectroscopy
Prepared samples were analyzed on a Bruker Avance II-700
spectrometer, operating at a proton frequency of 700.13 MHz. The
spectrometer is equipped with a BACS-60 automatic sample changer
and a 5 mm inverse TXI-Z probe when measuring serum samples.
Since the brain volume of rats is rather small, the amount of CSF that
can be collected at once from one animal is too small to perform a
classical NMR analysis (N100 μL is necessary, prior to dilution to the
ﬁnal 550 μL measuring volume, in order to get a good S/N). Combining
CSF taken from different animals within a population is not advisable,
since this will remove the possibility to detect individual differences.
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1 mm probe setup provides an alternative to address the measure-
ment of such volume restricted samples. Therefore, CSF samples
were measured with a 1 mm inverse TXI-Z probe, requiring only 8 μL
of sample volume. The samples were held at room temperature
while on the sample changer and at 303 K during acquisition. Carr–
Purcell–Meiboom–Gill (CPMG) experiments were executed in order
to get 1D 1H NMR spectra of the samples. The individual CPMG spin
echo (in total 1 ms) was repeated 20 times, resulting in a total spin-
spin relaxation delay of 20 ms. Suppression of the water signal was
performed using 2.22 s presaturation during the relaxation delay. For
serum 64 scans (32 K data points each) were sampled whereas 1024
scans were needed for CSF. Each scan had an acquisition time of 0.78 s.
To keep variation due to sample handling to a minimum, tuning and
matching as well as shimming were performed automatically for each
sample. Digital ﬁltering was performed using the ‘baseopt’ option
available in Topspin 2.0 (Bruker Biospin Corporation) which results in
ﬂat baselines. Prior to Fourier transformation, the Free Induction
Decays (FIDs) were zero-ﬁlled to 64 K and an exponential window
function with a line broadening factor of 0.3 Hz was applied. The
acquired NMR spectra were consecutively processed for phase and
baseline correction. In the absence of an external reference (vide
supra 2.2.2), all serum spectra were referenced to the methyl doublet
of lactate at 1.33 ppm. After initial referencing of the CSF spectra using
the anomeric glucose 1H signal at 5.225 ppm, the spectra were still
shifted one against the other. They were aligned using an in house
developed spectral alignment algorithm (Vu T.N. et. al, submitted).
2.4. Data reduction of the NMR spectra
The 1H NMR spectra were automatically reduced into consecutive
integrated spectral regions (buckets) of an equal width (0.05 ppm)
applying R (version 2.7.2, http://www.r-project.org). In order to
eliminate spectral variations due to different quality of water
suppression from one spectrum to another, the region containing
the water resonance (4.5–5.0 ppm) was not included in the analysis.
In order to account for differences in concentration between samples,
the subdivided spectra were scaled to their total intensity.
2.4.1. Multivariate analysis
Prior tomultivariate analysis, the datawere scaled to unit variance.
Besides unit variance scaling, also pareto scaling and no scaling were
tested on the dataset. However, these did not generate signiﬁcant
differences. Since all the variables possess an equal weight, irrespec-
tive of their absolute magnitude in the original data when unit
variance scaling is applied, this method was preferred.
Principal component analysis (PCA) is used to project the data in
two or three dimension in order to be able to discern outliers. This
method transforms the original variables in new, uncorrelated
variables or principal components (PC) in such a way that the ﬁrst
PC represents most of the variation present in the original dataset.
Higher PC will subsequently contain less amount of the variance
[5,7,26].
Partial least squares-discriminant analysis (PLS-DA) is a multivar-
iate classiﬁcationmethod based on PLS, a regression extension of PCA.
This technique uses a priori knowledge about the data to maximize
the separation between samples belonging to different classes [7,35].
Here, it concerns information about the pathological condition
(healthy or HD) of each sample. The obtained scores plots are used
to visualize the separation between the samples based on their class
membership. The corresponding loading plots contain information
about the variables responsible for the observed separation. Both PCA
and PLS calculations were performed with R (R version 2.7.2, http://
www.r-project.org, packages FactoMineR version 1.14, caret version
4.76). A double cross-validation (2CV) strategy and permutation test
[36] were applied to estimate the quality of the developed PLS-DAmodel. The data points were randomly divided into 5 fractions, of
which one was used for testing, whereas the others were used for
training and validation. Leave-one-out cross-validation (LOOCV) [36]
is used for validation in order to select the optimal model. LOOCV uses
all but one data point as the training set. The left-out data point is used
for validation. The data were randomly ordered 100 times. The
average of area under the ROC curve (AUROC) was used as the
criterion. In order to select the optimal number of components for
PLS-DA, different numbers were tested (from 1 to the number of
samples). Furthermore, the number of misclassiﬁcations and the Q²
value were collected. A distribution was generated for the H0
hypothesis that no difference exists between the two classes. In the
permutation test, the class labels of control and disease are
permutated by randomly assigning them to different individuals.
With ‘wrong’ class labels, a classiﬁcation model is again calculated.
The data were permutated 1000 times. For each permutated set, the
cross-validation was repeated 20 times and the average parameter
values were computed.
2.4.2. Univariate analysis
The bucket table created for the multivariate analysis was
exported to Excel (Microsoft Ofﬁce 2003) in order to carry out a
Student's t-test. P levels smaller than 0.05 were considered to be
signiﬁcant. An advanced classiﬁer, Support Vector Machine (SVM)
[37], was applied to classify the samples based on the signiﬁcantly
differential buckets. Each sample contains one out of two possible
labels, and is represented by a feature vector based on the values of
the signiﬁcant buckets. The data samples were randomly divided into
5 fractions, of which one was used for testing, whereas the others
were used for training and validation. The data were randomly
ordered 100 times. The average of area under the ROC curve (AUROC)
was used as the criterion. To estimate the quality of the developed
SVM model, the double cross-validation (2CV) strategy and permu-
tation test described in [36] used for PLS-DA were applied again. In all
experiments, the SVM function in the package e1071 (version 1.5-22)
in R (R version 2.7.2, http://www.r-project.org) was used with the
default setting parameters, e.g. linear kernel and cost equals 1.
3. Results
3.1. Visual inspection of NMR spectra
There is a lot of information comprised in 1HNMR spectra of serum
and CSF samples. Visual inspection of the spectra can already reveal
some interesting features in some cases. A representative 1H Carr–
Purcell–Meiboom–Gill (CPMG) serum spectrum of both a wild-type
and a transgenic HD rat is represented in Additional ﬁle A. The
projection of all available serum spectra onto each other makes a clear
differentiation between wild-type (WT) and HD rats possible. Peaks
representing glucose and succinic acid seem to be elevated in spectra
fromHD rats (Fig. 1). This indicates that both glucose and succinic acid
are increased in concentration in the serum of transgenic animals.
Visual examination of an overlay of the CSF spectra does not indicate
an immediate difference between WT and HD rats.
3.2. PCA to detect outliers
Principal component analysis (PCA) was applied on the data in
order to uncover inherent similarities and differences potentially
present within the spectral proﬁles. The scores plot of the ﬁrst two
principal components gives a representative overview of the data
(Fig. 2).
3.2.1. Serum samples
The ﬁrst principal component (PC1) accounts for 76.42% of the
total variation present in the dataset. The second principal component
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points lying outside the 95% conﬁdence ellipse (Hotelling T²) can be
considered as outliers, i.e. observations that have an aberrant
behaviour. As indicated in Fig. 2, two data point are laying outside
the Hotelling T² plot. Reconsidering these spectra reveals that the
water suppression technique, which has been used while acquiring
the spectra, has caused a shift of the baseline in comparison with the
other spectra. This slightly different prospect is revealed by this
multivariate statistical tool. However, these two spectra are not
discarded for further analysis, as their differences are not from a
biological nature.
3.2.2. CSF samples
The scores plot of the ﬁrst two principal components accounts for
45.57% of the total variation present in the CSF dataset. Possible
outliers present in the dataset were uncovered by spotting the data
points lying outside the 95% conﬁdence ellipse of this scores plot.Fig. 1. Visual comparison of serum spectra. An overlay of all acquired 1H NMR 700 MHz ser
wild-type rats are coloured black; those of HD rats blue.Consecutive PCA indicate three data points (one WT and two HD
samples) with an aberrant behaviour (see Additional ﬁle B, Additional
ﬁle C and Additional ﬁle D). Those spectra correspond with low
available volume samples (b40 μL lyophilized). For this reason, these
spectra were excluded from the dataset before further analysis.
3.3. Discrimination between normal and pathological samples using PLS-
DA
A partial least squares-discriminant analysis (PLS-DA) model was
developed in order to discriminate samples according to their class
membership, i.e. healthy or HD. The results of this analysis are
depicted in Fig. 3. The scores plot shows a reasonable separation
between both sample groups. The corresponding loading plot reveals
the metabolites that are responsible for the observed separation.
Annotation of the loadings was conﬁrmed by a comparison with
reference spectra of an in house database recorded at 700 MHz. Aum spectra, a some representative peaks of glucose b signal of succinic acid. Spectra of
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Fig. 2. PCA to detect outliers. PCA scores plot of the ﬁrst and second principal component
mapping the serum spectra of twelve wild-type and ten HD rats (females, 2 months old).
The Hotelling T2 ellipse is used to elucidate outliers. Colour coding: black squares=wild-
type rats, blue triangles = HD.
1375K.A. Verwaest et al. / Biochimica et Biophysica Acta 1812 (2011) 1371–1379double cross-validation (2CV) strategy and permutation test were
applied to estimate the quality of the developed PLS-DA model, as
described in [36]. This yielded an area under the ROC curve (AUROC)
of 84.90% and 72.73% for serum and CSF respectively. For all
assessment parameters (Q² value and the number of misclassiﬁca-
tions), there is a clear distinction between the permutation distribu-
tion and the original classiﬁcation. This shows that the speciﬁc
classiﬁcation is signiﬁcant (see Additional ﬁles E1 for serum and E2 for
CSF).
3.3.1. Serum samples
The loading coefﬁcients responsible for the separation of the
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Fig. 3. PLS, clustering of samples according to their pathological condition. a PLS scores plot o
rats (females, 2 months old). b The corresponding loading plot represents the variables attrib
wild-type (black squares) and eight HD (blue triangles) rats (females, two months old). dto the metabolites glucose (δ3.28, δ3.38, δ3.43, δ3.48, δ3.53, δ3.73,
δ3.78, δ3.83, δ3.88, δ3.93 and δ5.23), lactate (δ1.33 and δ4.13), lipids
(δ0.83, δ0.88, δ1.23, δ1.28, δ1.58, δ2.03, δ2.23, δ2.73, δ2.78, δ5.28 and
δ5.33), succinic acid (δ2.43), glutamine (δ2.13 and δ2.43) and NAA
(δ2.03). An overview of these results is given in Table 1.
3.3.2. CSF samples
The most relevant loadings in the separation of CSF samples
according to their pathological condition are situated around δ3.38,
δ3.43, δ3.48, δ3.73, δ3.78, δ3.83 and δ3.88 (glucose) and δ1.33
(lactate).
3.4. Discrimination between normal and pathological samples using a
univariate analysis
A Student's t-test is used to uncover the metabolites that show a
statistically signiﬁcant concentration difference between the two
observed populations. Thus, these metabolites can be used to
differentiate HD from healthy samples. The bucket table, which was
created for the multivariate analysis, was used as input variable for
the univariate analysis. For each bucket, the corresponding p-value
was calculated. A p-value smaller than 0.05 was considered as
signiﬁcant.
3.4.1. Serum samples
The bucket comprising both the singlet peak of the methylene
groups of succinic acid and the multiplet peak of CH2CO of glutamine
was found to be signiﬁcantly different between WT and TG rats. In
order to assign this statistically signiﬁcant difference unambiguously
to the correct metabolite, both signals were integrated referenced to
the methylene singlet of creatine at 3.93 ppm. A visual representation
of these results is displayed in Fig. 4. These boxplots reveal that both
metabolites contribute to the differentiation of the samples according0e+00 1e 041e 04 2e 04 3e 04
0.
00
02
0
0.
00
01
5
0.
00
01
0
0.
00
00
5
0.
00
00
0
0.
00
00
5
loadings WT vs TG
comp1
co
m
p2
0to0.050. 5to0.10.1to0.15. 5to0.2.2t .20. 5to0.3.3to0.350. 5to0.40.4to0.450.45to0.50.5to0.550.55to0.60.6to0.650.65to0.7
0.7to0.75
0.75to0.8 0.8to0.85
0.85to0.9
0.9to0.95
1to1.05
1.05to1.1
1.1to1.15
1.2to1.25
1.25to1.3
1.35to1.4
1.5to1.55
1.55to1.6
1.6to1.65
1.95to2
2to2.05
2.05to2.1
2.2to2.25
2.65to2.7
2.7to2.75
2.75to2.8
2.8to2.85
3.15to3.2
4to4.0
4.05to4.1
4.2to4.25
4.25to4.3
5to5.05
5.05to5.1
5.1to5.15
5.15to5.2 5.25to5.3
5.3to5.35
5.85to5.9.9to5 955.95to66to6.056.05to6.1.1to6.156. 5to6.22t .2. t .33to6.356. 5to6.44 4.7t 6.79t .97 45to7..6t 7.68.8t .8
9.6to9.6585to9.9
0.95to1
1.15to1.2
1.3to1.35
1.4to1.45
1.45to1.5
1.65to1.71.7to1.75
1.75to1.8
1.8to1.851.85to1.9
1.9to1.95
2.1to2.15
2.15to2.2
2.25to2.32.3to2.352.35to2.42.4to2.45
2.45to2.5
2.5to2.55
2.55to2.62.6to2.652.85to2.9
2.9to2.952.95to33to3.05
3.05to3.1
3.1to3.15
3.2to3.25
3.25to3.3
3.3to3 35
3.35to3.4
3.4to3.45
3.45to3.5
3.5to3.55
3.55to3.6
3.6to3.6
3.65to3.7
3.7to3.75
3.75to3.8
3.8to3.85
3.85to3.9
3.9to3.95
3.95to4
4.1to4.15
4.1 t 4.2
4.3to4.354.3 to4.44.4to4.45
4.45to4.5
5.2to5.25
5.35to5.4
5.4to5.45
5.45to5.55.5to5.555.55to5.65.6to5.655.6 t 5.75.7to .755.75to5.8.8t . 56. 5to6.55to6.5t .6.6t .6 77 88 8.8 t .96.95to77t 7.057.0 t .11t 7.17 2.2to .27 5 o 33 353 44. t 7. 55to7.6 7.85to7.99to7.957.9 to88t 8.08 t 8.11t 8.1. 222 o 33 344 45 5t .66to .65778.7 t 8.88 899t 8.98.95to99to9.059 05 o9 1.1t 9.15t .22 233t .44 456.6 77 .789 8 89 9.95to 0
8e 04 6e 04 4e 04 2e 04 0e+00 2e 04
1e
04
8e
05
6e
05
4e
05
2e
05
0e
+0
0
2e
05
4e
05
loadings
comp1
co
m
p2
0.1to0.15
0.8to0.85
1to1.051.05to1.1
1.5t 1.51.55to1.6
1.8to1.85
1.85to1.9
2.1to2.15
2.15to2.2
2.2to2.25
2.6to2.65
2.7to2.75
3.2to3.253.25to3.3
3.35to3.4
3.4to3.45
3.45to3.5
3.5to3.55
3.55to3.6
3.6to3.65
3.65to3.7
3.7to3.75
3.75to3.8
3.8to3.85
3.85to3.9
3.9to3.95
3.95to4
4. 5to4.2
4.25to4.34.3to4.35. 5to4.44.4to4.454.4 t .55 t .65to5.055 0 5 1
5.2to5.25
5.25to5.35.3to5.35
3. t .5to5.5 56t .677 788 85.85to5.9.9 to66to6.056 1 6 22 6 2t .36 364 67 8
8 6 86 8 t 6.9.9t .96.95to77t 7.7 77 t 7.227 73 37 44 47 55 t .66 677 7 99 7 97 88to .058 0 8 1
8.1to8.158 88.45 t .6
78 888 99 99 t 9.9 9 19 2 9 39. t .. t . 88 9100to0.05
0.05to0.1.1 t .20.2to0.252 33to0.3544t .44
0.5to0.555to0.6.6t .60.65to0.7.7to0.75
0.75to0.8
0.85to0.90.9to0.950.95to1
1.1to1.15
1.15to1.21.2to1.25
1.25to1.3
1.3to1.35
1.35to1.4
1.4to1.45
1.45 1 5
1.6 1 6
1.65to1.7
1.7to1.751.7 t 1.8
1.9to1.95
1.95to2
2to2.05
2.05to2.1
2.25to2.32 3to2.352.35to2.4
2.4to2.45
2.45to2.5
2. 2 55
2.55to2.6
.6 t 2.7
2 22 8 2 8. t .9
9 2 9
2.95to3
3to3.05
3.05to3.13.1t 3.3.15to .23.3t .35
4to4.05
4 4
4.1to4.15
4.2to4.25
4.5to4.55
5.1t 5.15.15to5.2
5.9t 5.96 66. to6. 54 45 5
7 7 7.8 7 8
8.1 t 8.22to8.258.2 t 8.38 35to8.48 to8. 58 89 t .99 5 t 9.66 679 9 9
f
1
H NMR serum spectra of twelve wild-type (black squares) and ten HD (blue triangles)
utable to the observed class separation. c PLS scores plot of 1H NMR CSF spectra of nine
The loading coefﬁcient plot corresponding to the scores plot (c).
Table 1
Overview of the metabolites responsible for the separation of serum samples according
to their pathological condition.
Metabolites
Higher concentration in TG animals Glucose
Lactate
Succinic acid
Glutamine
Lower concentration in TG animals NAA
Lipids
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(pb0.005) were found to be signiﬁcantly increased in HD rats
compared to WT littermates. Glucose was found to be elevated in
HD rats as well (pb0.05). Furthermore, NAAwas decreased in HD rats
(pb0.05). Moreover, the bucket comprising the area between 4.30
and 4.25 ppm (see Fig. 5) is found to be signiﬁcantly decreased in HD
rats. At present, we have not been able to identify the component(s)HD wt
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Fig. 4. Visualization of the results obtained by univariate analysis. A boxplot is used to visua
i.e. the median (black line), 25% quartile (lower box line), 75% quartile (upper box line), m
data points are situated in the box. The range between the 25% quartile (Q25) and 75% q
calculated by the formula flower=Q25−1.5* IQR for the lower whisker and respectively fuppe
component in the bucket comprising the area between 4.30 and 4.25 ppm and e succinic aci
blue colour.present in this bucket. These results are illustrated in Fig. 4. The
thirteenmost signiﬁcant buckets for whom the p-value is smaller than
0.05, able in discriminating between healthy and HD samples, were
used to build an SVM classiﬁer. An area under the ROC curve (AUROC)
of 71.44% could be obtained. For all the assessment parameters, a clear
distinction between the permutation distribution and the original
classiﬁcation is obtained. This demonstrates that the speciﬁc
classiﬁcation is signiﬁcant (see Additional ﬁle E3).
3.4.2. CSF samples
In CSF, a Student's t-test could not reveal any statistically
signiﬁcant metabolite concentration difference between WT and HD
rats.
4. Discussion
In this study we have shown that rats transgenic for the HD
mutation can be discriminated from healthy, wild-type littermatesHD wt
2.
8
3.
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HD wt
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lize the data of the Student's t-test. The boxplot is based on the ﬁve-number-summary,
inimum (lower whisker) and maximum (upper whisker). This means that 50% of the
uartile (Q75) is called the interquartile range (IQR). Subsequently, the whiskers are
r=Q75+1.5* IQR for the upper whisker. a glucose, b glutamine, c NAA, d the unknown
d. The boxplot of WT samples is coloured grey whereas the boxplot of TG samples has a
Fig. 5. Spectral region between 4.35 and 4.25 ppm. The univariate analysis indicates the bucket comprising the chemical shift region between 4.30 and 4.25 ppm as signiﬁcantly
different between WT and HD rats. The signals within this bucket are illustrated.
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already executed by Tsang and co-workers on a different animal
model [27]. However, there are some inconsistencies between the
ﬁgures and text described in their paper. The metabolites they
indicated in the loading plot of the serum samples correspond to those
mentioned for urine samples in the text and vice versa.
We used three differentmethods for the analysis. Visual inspection
of the serum spectra already suggests that glucose as well as succinic
acid levels are elevated in HD rats. These results are statistically
conﬁrmed by means of a univariate analysis. Moreover, the Student's
t-test discloses that glutamine and NAA are able to discriminate
between HD and WT rats in serum samples. PLS, a supervised
multivariate statistical technique, was performed in order to reveal
the discriminative power of different metabolites between the
studied groups. For the serum samples, the loadings which are able
to separate healthy from pathological samples correspond to the
metabolites glucose, glutamine, lipids, lactate, succinic acid and NAA.
Regarding CSF spectra, visual inspection and univariate analysis are
not able to discriminate WT from HD rats. PLS, on the other hand,
distinguishes both glucose and lactate as discriminating metabolites.
In CSF as well as in serum samples, glucose is indicated as a
biomarker to detect Huntington disease presymptomatically. Al-
though the literature [2,4,39] exposes some evidence of diabetes in
subjects with HD, plasma glucose measurements in the same
transgenic rat model at different ages do not reach the threshold for
diabetes [28]. Thus, the observed difference in glucosemust have been
caused by a perturbation in another metabolic pathway. Some
evidence of a disturbed glucose metabolism in HD can be found in
the literature [4,40,41]. A possible explanation for the observed
increased concentrations of glutamine and glucose is also documen-
ted: according to Sibson et al. [32], there is a 1:1 stoichiometry
between the consumption of glucose and the formation of glutamate.
The observed increase in glutamine can reﬂect a decreased glutamin-
ase activity. Glutaminase is a mitochondrial enzyme found in neurons
that takes care of the conversion of glutamine in glutamate. A
perturbation of the glutamate–glutamine cycling may indicate an
impairment of energymetabolism andmitochondrial respiration [27].
Thus, a decrease in glutaminase activity precludes the conversion of
glutamine into glutamate. Owing to this, the neurons will have a lack
of glutamate for neurotransmission. Finally, this will result in an
elevated concentration of glutamine and glucose (due to decreasedglucose utilization) as observed in our experiments [4]. This theory
can be afﬁrmed by previous studies which also point to a disruption of
energy metabolism in HD [42,43].
In addition, the observed difference in lactate supports the theory
of a deﬁciency of oxidative energy metabolism in rats transgenic for
HD. The conversion of glucose to pyruvate during glycolysis involves
the concomitant reduction of 2 mol of NAD+ to NADH. In cells
undergoing an aerobic respiration, pyruvate is subsequently oxidized
to acetyl-Coenzyme A (Acetyl-CoA), which in turn, enters the citric
acid cycle. In this way, the NADH produced during glycolysis is
reoxidized through the mitochondrial electron transport chain.
However, a perturbation in the Krebs cycle or mitochondrial electron
transport chain might prevent pyruvate to enter the oxidative energy
metabolism. Since NADH needs to be reoxidized to NAD+ to maintain
a steady state condition, an alternative pathway to transfer electrons
is accomplished, i.e. the reduction of pyruvate to lactate by the
catalyzed reaction of lactate dehydrogenase. As a result, an increased
concentration of lactate, the end product of anaerobic glycolysis,
indicates a defect in energy metabolism as well [44].
An elevated concentration of succinic acid is probably due to an
inhibition of succinate dehydrogenase. This enzyme has two important
functions in the mitochondria. First, it supports the oxidation of succinic
acid to fumarate in the tricarboxylic acid (TCA) cycle. Second, it is linked to
the respiratory chain, i.e. complex II of the mitochondrial electron
transport chain [45,46]. A decrease in mitochondrial complex II activity
has already been observed in HD [3,47,48]. Our ﬁnding of an elevated
succinic acid concentration is therefore in linewith these previous results.
A decreased NAA concentration is known to be a marker of
neuronal dysfunction [27,49]. Reduced NAA levels have been well
documented for several neurological diseases, e.g. Alzheimer disease
[50], Huntington disease [4,27,51] and Parkinson disease [17,50].
Moreover, in HD it clearly correlates with the duration of symptoms
and the CAG repeat length [16,52]. The enzyme responsible for the
synthesis of NAA, L-N-acetylaspartyl transferase, is exclusively found
inmitochondria [50]. Since inhibitors of themitochondrial respiratory
chain seem to decrease the concentration of NAA [4], reduced NAA
levels may reﬂect an impaired mitochondrial energy production [27].
Obviously, a change in the concentration of eachof thesemetabolites
can be linked to a variety of conditions. However, the changes observed
for all metabolites combined could allow for amore narrow correlation,
i.e. with HD.
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In conclusion, this study shows that metabolic alterations already
emerge in the serum and CSF of these rats before overt symptoms of
HD are manifested. In an early stage of the disease, metabolic
alterations seem to be more pronounced in serum compared to CSF.
All metabolites found being able at discriminating WT from HD rats
point to a disruption of the mitochondrial respiratory chain and
energymetabolism. These ﬁndings suggest that compounds which act
on mitochondria might have a positive effect on HD pathology.
Moreover, this study shows that 1H NMR spectroscopy is an
appropriate tool to investigate the metabolic disturbance occurring
in early stages of HD. A more profound knowledge of the disease
pathology can be obtained by performing a metabolomic analysis of
samples originating from more mature rats. Such an analysis could
give more insight into the development of this disease, which in turn
may lead to improved therapeutic interventions.
Supplementarymaterials related to this article can be found online
at doi:10.1016/j.bbadis.2011.08.001.
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